CYC116 sensitivity varied substantially among leukemia cell lines in a four-day viability assay, including weaker responses in HL-60 cells and measurable effects on normal bone-marrow stroma. In mouse mast cells, CYC116 inhibited antigen-induced degranulation (IC50 ∼1.42 µM), while calcium-mobilization bypass controls remained responsive. [1,2]
Four-day CYC116 cytotoxicity profile with normal-cell controls
Cell-based study · Fourteen leukemia cell lines (B-ALL, T-ALL, AML and APML), normal lymphocytes and bone-marrow stroma [1]
Responses varied across the cell panel; normal bone-marrow stroma was also affected within the tested range. Values below are reported IC50 ± SD, representative of three separate experiments; they are assay endpoints, not administered treatment doses.
Literature-Reported Treatment Conditions
- Treatment concentration
- Eight concentrations spanning 1×10−6 to 10 µM
- Exposure duration
- 4 days before viability readout
- Method
- Alamar blue assay or automated microscopy; comparison to DMSO-treated controls
- Vehicle
- DMSO; final fraction not specified
- Reported limits
- The table does not assign a specific readout method to each model.
Methods and source locations
Compound reported in the paper: CYC116; Compound label in the paper: CYC116
Evidence for literature CYC116 in the stated models; no Adooq-lot validation or salt-equivalence claim.
Table 2, CYC116 rows and footnote; Materials and Methods: Aurora Kinase Inhibitors; Cytotoxicity Assays
C1, SEM, B1, UOCB1, Nalm6 and KOPN8 cell viability: Four-day cytotoxicity profiling; three separate experiments, triplicate wells. — Table 2, upper CYC116 row
CEM and Molt-3 cell viability: Same four-day profiling experiment. — Table 2, upper CYC116 row
Molm13, MV4-11 and TIB-202 cell viability: Same four-day profiling experiment. — Table 2, lower CYC116 row
NB4, HL-60 and HL-60 RA cell viability: Same four-day profiling experiment. — Table 2, lower CYC116 row
Normal lymphocyte and bone-marrow stromal viability: Same four-day profiling experiment; >10 is a reported bound, not an exact value. — Table 2, lower CYC116 row, normal-cell columns
Cellular Aurora phosphorylation and apoptosis-marker readouts
Cell-based study · C1 and KOPN8 B-ALL cells [1]
The CYC116 lanes showed reduced phospho-Aurora signal and cleavage of PARP and caspase 7 relative to the corresponding DMSO control. This is qualitative cellular pathway evidence, not a purified-enzyme potency or isoform-selectivity measurement.
Literature-Reported Treatment Conditions
- Treatment concentration
- 1 µM
- Exposure duration
- 18 h
- Method
- Immunoblotting for total Aurora-A/B, phospho-Aurora-A/B/C, PARP and caspase 7; β-actin loading control
- Vehicle
- DMSO; CYC116 compared with DMSO1
- Reported limits
- No densitometric effect size or enzyme IC50 is reported for this experiment.
Methods and source locations
Compound reported in the paper: CYC116; Compound label in the paper: CYC116
Evidence for literature CYC116 in the stated models; no Adooq-lot validation or salt-equivalence claim.
Figure 3 and caption; Results: Aurora Kinase Inhibition By Targeted Therapeutics; Materials: Immunoblotting
Phospho-Aurora signal and PARP/caspase-7 cleavage: Representative of three separate experiments; β-actin loading control. No exact band-intensity values inferred. — Figure 3, CYC lanes versus DMSO1 in C1 and KOPN8 panels; caption
Antigen-induced mast-cell degranulation and calcium-bypass controls
Cell-based study · IgE-sensitized mouse bone-marrow-derived mast cells (BMMCs) [2]
CYC116 inhibited antigen-induced β-hexosaminidase release. The same concentration range did not inhibit degranulation elicited by ionomycin or thapsigargin, limiting the effect to the tested upstream activation context.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0.2, 1 and 5 µM
- Exposure duration
- 30 min pretreatment; 15 min stimulation
- Method
- β-Hexosaminidase release relative to total enzyme; antigen challenge 50 ng/ml DNP-HSA. Bypass controls used ionomycin (1 µM) or thapsigargin (300 nM).
- Reported limits
- Drug vehicle and final solvent fraction not specified in the read methods. Figure 2B washout and Figure 2C viability are excluded from adopted claims.
Methods and source locations
Compound reported in the paper: CYC116; Compound label in the paper: CYC116
Evidence for literature CYC116 in the stated models; no Adooq-lot validation or salt-equivalence claim.
Figure 2A; Figure 5A–B; Results: Effect of CYC116 on β-hexosaminidase release; Materials: Preparation and stimulation of BMMCs; Measurement of β-Hexosaminidase release
Antigen-induced degranulation: β-Hexosaminidase release; antigen-only and unstimulated controls; PP2 comparator at 10 µM. Means ± SEM from three independent experiments in triplicate. — Figure 2A and associated Results paragraph
Ionomycin- or thapsigargin-induced degranulation: Means ± SEM from three independent experiments in triplicate; matched stimulant-only and unstimulated controls. No exact percentage values inferred. — Figure 5A–B and caption; Results: Effect of CYC116 on calcium influx-induced degranulation